May 2026 Ypsomed expanded its autoinjector platform portfolio with YpsoLoop and large-volume YpsoMate solutions, supporting pharmaceutical companies developing self-administered biologic therapies for markets including Australia.
March 2026 SHL Medical expanded its large-volume autoinjector portfolio with cartridge-based delivery platforms designed for high-viscosity and higher-volume biologic formulations.
December 2025 Australian healthcare providers expanded patient-training and support programs for self-administered biologic medicines supplied through prefilled autoinjectors, supporting treatment outside hospital environments.
September 2025 Pharmaceutical companies expanded the Australian availability of autoinjector-based biologic therapies for inflammatory, allergic, migraine, and autoimmune conditions through new product registrations and reimbursement initiatives.
June 2025 Australian allergy organizations and healthcare providers expanded education initiatives covering adrenaline autoinjector selection, storage, administration, and emergency anaphylaxis management.